Shopping Cart

No products in the cart.

neoplasms

Weight Loss in Cancer and the 2017 Common Terminology Criteria for Adverse Events-Dangerous and Misleading.

Accurate toxicity reporting in cancer clinical trials is necessary to promote regulatory decision making. Up to 85% of those with some cancers (e.g., oesophagus, head and neck, and pancreas) experience significant progressive weight loss (WL) throughout treatment. Therefore, it is...
๐Ÿ—“๏ธ 2025-04-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreWeight Loss in Cancer and the 2017 Common Terminology Criteria for Adverse Events-Dangerous and Misleading.

Associations Between Exercise Training, Physical Activity, Sedentary Behaviour and Mortality: An Umbrella Review of Meta-Analyses.

Numerous studies support the association of exercise training, physical activity (PA) and sedentary behaviour (SB) with both mortality and morbidity outcomes. The results across studies have been inconsistent, and no umbrella reviews have yet been conducted on this topic. We...
๐Ÿ—“๏ธ 2025-04-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAssociations Between Exercise Training, Physical Activity, Sedentary Behaviour and Mortality: An Umbrella Review of Meta-Analyses.

Multicomponent Interventions for Adults With Cancer Cachexia: A Systematic Review.

Cancer cachexia has substantial impacts on people's quality of life. There is no current gold standard treatment, but the complex pathophysiology of cachexia suggests that a multitargeted and individualised treatment approach is needed. We aimed to evaluate the extent to...
๐Ÿ—“๏ธ 2025-04-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMulticomponent Interventions for Adults With Cancer Cachexia: A Systematic Review.

Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

Cancer cachexia presents a significant challenge, but the ghrelin agonist anamorelin shows promise as a potential treatment. This study examined whether the baseline systemic inflammatory response (SIR) (measured by the modified Glasgow Prognostic Score [mGPS]), low BMI or greater weight...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAnamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

Cachexia Alters Central Nervous System Morphology and Functionality in Cancer Patients.

Cachexia is a clinically challenging multifactorial and multi-organ syndrome, associated with poor outcome in cancer patients, and characterised by inflammation, wasting and loss of appetite. The syndrome leads to central nervous system (CNS) function dysregulation and to neuroinflammation; nevertheless, the...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCachexia Alters Central Nervous System Morphology and Functionality in Cancer Patients.

Aged-Related Fibroblast Activation Protein Expression in Skeletal Muscles Evaluated by PET Imaging.

Fibroblast activation protein (FAP) is prominently involved in the tumour microenvironment and tissue remodelling processes in most cancers, and its expression is also noted in normal skeletal muscle. This study aims to explore the relationship between FAP expression and age-related...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAged-Related Fibroblast Activation Protein Expression in Skeletal Muscles Evaluated by PET Imaging.

Corrigendum to "Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge" Am J Clin Nutr 116 (2022) 1229-1239.

๐Ÿ—“๏ธ 2025-02-12
๐Ÿ“ฐ Publication: American Journal Of Clinical Nutrition
Read MoreCorrigendum to "Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge" Am J Clin Nutr 116 (2022) 1229-1239.

Diagnostic Criteria for Cancer-Associated Cachexia: Insights from a Multicentre Cohort Study.

To explore the association between cachexia, as defined by different diagnostic criteria, and the risk of mortality in individuals with cancer. We also examined which diagnostic criteria are more feasible and appropriate for cancer-associated cachexia in clinical practice. A multicentre...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDiagnostic Criteria for Cancer-Associated Cachexia: Insights from a Multicentre Cohort Study.

Mechanisms and pharmacotherapy of cancer cachexia-associated anorexia.

Cachexia is a multifactorial metabolic syndrome characterized by weight and skeletal muscle loss caused by underlying illnesses such as cancer, heart failure, and renal failure. Inflammation, insulin resistance, increased muscle protein degradation, decreased food intake, and anorexia are the primary...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Pharmacology Research & Perspectives
Read MoreMechanisms and pharmacotherapy of cancer cachexia-associated anorexia.

Early identification of potentially reversible cancer cachexia using explainable machine learning driven by body weight dynamics: a multicenter cohort study.

Cachexia is associated with multiple adverse outcomes in cancer. However, clinical decision-making for oncology patients at the cachexia stage presents significant challenges. This study aims to develop a machine learning (ML) model to identify potentially reversible cancer cachexia (PRCC). This...
๐Ÿ—“๏ธ 2025-01-08
๐Ÿ“ฐ Publication: American Journal Of Clinical Nutrition
Read MoreEarly identification of potentially reversible cancer cachexia using explainable machine learning driven by body weight dynamics: a multicenter cohort study.

Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.

Anorexia is a major cause of cancer cachexia and is induced by growth differentiation factor-15 (GDF15), which activates the rearranged during transfection (RET) protein tyrosine kinase in the hindbrain through GDF family receptor ฮฑ-like (GFRAL), raising the possibility of targeting...
๐Ÿ—“๏ธ 2025-01-06
๐Ÿ“ฐ Publication: Cancer Letters
Read MoreSelpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.

Prevalence and Prognostic Significance of Sarcopenia in Gynecologic Oncology: A Systematic Review and Meta-Analysis.

Sarcopenia in gynaecologic oncology patients has garnered increasing attention, but its prevalence has not been comprehensively summarized. This study aims to integrate the prevalence of sarcopenia in this population through systematic evaluation and meta-analysis, providing a reference for future clinical...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrevalence and Prognostic Significance of Sarcopenia in Gynecologic Oncology: A Systematic Review and Meta-Analysis.

Brown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Brown adipose tissue (BAT) has been mainly investigated as a potential target against cardiometabolic disease, but it has also been linked to cancer-related outcomes. Although preclinical data support that BAT and the thermogenic adipocytes in white adipose tissue may play...
๐Ÿ—“๏ธ 2024-12-30
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreBrown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-ฮบB signaling and oxidative stress.

Cancer-associated cachexia (CAC) is a severe metabolic disorder syndrome mainly characterized by muscle and fat loss, which accounts for one-third of cancer-related deaths. No effective therapeutic approach that could fully reverse CAC is available. NF-ฮบB signaling and oxidative stress play...
๐Ÿ—“๏ธ 2024-04-08
๐Ÿ“ฐ Publication: Genes & Diseases
Read MoreNovel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-ฮบB signaling and oxidative stress.

Metabolic interplays between the tumour and the host shape the tumour macroenvironment.

Metabolic reprogramming of cancer cells and the tumour microenvironment are pivotal characteristics of cancers, and studying these processes offer insights and avenues for cancer diagnostics and therapeutics. Recent advancements have underscored the impact of host systemic features, termed macroenvironment, on...
๐Ÿ—“๏ธ 2025-01-20
๐Ÿ“ฐ Publication: Nature Reviews Cancer
Read MoreMetabolic interplays between the tumour and the host shape the tumour macroenvironment.

Systemic metabolic crosstalk as driver of cancer cachexia.

Cachexia is a complex metabolic disorder characterized by negative energy balance due to increased consumption and lowered intake, leading to progressive tissue wasting and inefficient energy distribution. Once considered as passive bystander, metabolism is now acknowledged as a regulator of...
๐Ÿ—“๏ธ 2025-01-04
๐Ÿ“ฐ Publication: Trends In Endocrinology And Metabolism
Read MoreSystemic metabolic crosstalk as driver of cancer cachexia.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!